Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALPG | P10696 | 2/20 | 0.45 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199143 | 0.81 | MAP2K1 (0.47) | VNN1MAPK14SMN1; SMN2ALDH1A1HSD17B14 | |
| SCHEMBL4079787 | 0.81 | HSD17B14 (0.55) | VNN1SMN1; SMN2ALDH1A1HSD17B14CES2 | |
| SCHEMBL4537134 | 0.81 | CES2 (0.63) | ALDH1A1CES2CES1HTTCA1 | |
| SCHEMBL7935350 | 0.81 | VNN1 (0.60) | VNN1MAPK14SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6545581 | 0.80 | HNF4A (0.49) | MAPK14SMN1; SMN2LMNAALDH1A1ALPG | |
| SCHEMBL3950626 | 0.80 | HSD17B14 (0.51) | VNN1SMN1; SMN2HSD17B14ESR1GRM5 | |
| SCHEMBL907865 | 0.79 | MAPK14 (0.46) | VNN1MAPK14SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6505737 | 0.78 | MAPK14 (0.45) | VNN1MAPK14SMN1; SMN2LMNAALDH1A1 | |
| Bromide SCHEMBL3619165 | 0.78 | MAPK14 (0.45) | VNN1MAPK14SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30361968 | 0.78 | MAP2K1 (0.51) | VNN1HSD17B14GRM5P4HBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | VNN1 4654/4885MAPK14 30/4885SMN1; SMN2 3993/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | VNN1 4499/4885MAPK14 37/4885SMN1; SMN2 4475/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | VNN1 2798/4885MAPK14 2540/4885SMN1; SMN2 4456/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | VNN1 4439/4885MAPK14 37/4885SMN1; SMN2 4521/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | VNN1 4499/4885MAPK14 37/4885SMN1; SMN2 4475/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | VNN1 4443/4885MAPK14 110/4885SMN1; SMN2 3688/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | VNN1 4239/4885MAPK14 74/4885SMN1; SMN2 4048/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | VNN1 4492/4885MAPK14 111/4885SMN1; SMN2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.